Spironolactone (SPI), a pharmaceutical drug, was the pioneering mineralocorticoid receptor (MR) antagonist developed for the treatment of hypertension, primary hyperaldosteronism, and peripheral oedema associated with heart failure, as well as other aldosteronism-associated conditions. This evidence concerns the gene NR3C2 and hypertensive disorder.